ASH 2024 | Tagraxofusp demonstrates anti-tumor activity without myelosuppression in patients with BPDCN
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, comments on the results of a subanalysis from the pivotal Phase I/II trial (NCT02113982) of single-agent tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), highlighting the agent’s anti-tumor activity without the presence of significant myelosuppression. This finding is particularly encouraging, as it suggests that, in the future, tagraxofusp can be used in combination with other agents that cause mild myelosuppression. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We reported the analysis from the original pivotal trial of tagraxofusp in BPDCN. There were several stages of the trial, but we wanted to look at the myelotoxicity against normal hematopoiesis because the drug is targeting CD123, which is expressed in normal stem cells, so there’s always concern that it will add myelosuppression. Fortunately, the results show that as a single agent, it doesn’t really have any myelosuppression, so patients who started with low counts especially like platelets or neutrophil count in cycle one because of their disease, they in fact improved their counts by cycle two and subsequent cycles were not associated with myelosuppression and did not require any delays due to that and there were no increased infection complications...
We reported the analysis from the original pivotal trial of tagraxofusp in BPDCN. There were several stages of the trial, but we wanted to look at the myelotoxicity against normal hematopoiesis because the drug is targeting CD123, which is expressed in normal stem cells, so there’s always concern that it will add myelosuppression. Fortunately, the results show that as a single agent, it doesn’t really have any myelosuppression, so patients who started with low counts especially like platelets or neutrophil count in cycle one because of their disease, they in fact improved their counts by cycle two and subsequent cycles were not associated with myelosuppression and did not require any delays due to that and there were no increased infection complications. And this was independent of whether people patients had or did not have marrow involvement. I think this is really encouraging data because I think eventually we want to combine this drug with other agents that may have like myelosuppression and having something that is really very effective but not causing myelotoxicity is really promising.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Auxenion GmbH: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Janssen: Consultancy, Other: clinical trials; Klondike Biopharma: Research Funding; Curis: Consultancy; Sanofi Aventis: Consultancy; Servier: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Legend Biotech: Membership on an entity’s Board of Directors or advisory committees; Adaptive: Consultancy; MEI Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Intellisphere: Speakers Bureau; Dark Blue Therapeutics: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: clinical trials, Research Funding; Menarini Group: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Vincerx: Consultancy.
